<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943396</url>
  </required_header>
  <id_info>
    <org_study_id>FNHK2013/01</org_study_id>
    <secondary_id>IGA-NT14037-4/2013</secondary_id>
    <nct_id>NCT01943396</nct_id>
  </id_info>
  <brief_title>Treatment of AMD With Rheohemapheresis /RHF/</brief_title>
  <acronym>TARHF</acronym>
  <official_title>Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research rheohemapheresis will be used for the treatment of patients with high-risk
      dry form of age-related macular degeneration. Correction of rheologic parameters and
      activation of retinal functional reserves after the therapy will positively influence
      functional condition of retina. The newest special electrophysiologic methods will be used to
      determine retinal changes in time. The investigators will also evaluate some important
      immunologic factors and complement changes as well as define indication criteria more
      precisely.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With optimized therapeutic protocol we would prevent progression of the dry form of AMD into
      its devastating wet form and stabilize the situation. We suppose that retinal morphologic and
      functional conditions would improve in a high percentage of patients. Also possible technical
      and economic savings would not be less important with our own therapeutic protocol,
      especially, when blindness could be prevented.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electroretinography</measure>
    <time_frame>2.5 years</time_frame>
    <description>Evaluation of functional changes in single retinal layers and areas by newest special electrophysiologic methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunologic parameters changes</measure>
    <time_frame>2.5 years</time_frame>
    <description>To verify till undescribed changes of complement, some cytokines,factors monitoring endothelial function, and apoptosis markers, important for rapid repair of retinal revitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Rheohemapheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without rheohemapheresis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Into the group the patients will be randomized with the same disease but without rheohemapheresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>rheohemapheresis</intervention_name>
    <description>Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.</description>
    <arm_group_label>Rheohemapheresis</arm_group_label>
    <other_name>rheopheresis</other_name>
    <other_name>double plasma filtration</other_name>
    <other_name>cascade filtration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with AMD in the stage of soft drusen, grade 1-3 according to European Eye Study
        (EURYEYE) (see reference No 1), body weight over 50 Kilo and with other feasible
        indications for aphereses therapy (peripheral veins allowing vascular access to establish
        the extracorporal circuit).

        Exclusion Criteria:

          -  Study eye with exudative AMD

          -  Study eye with concomitant retinal or choroidal disorder other than AMD

          -  Study eye with significant central lens opacities and/or conditions that limit the
             view of the fundus

          -  uncontrolled diabetes, uncontrolled arterial hypertension

          -  insufficient antecubital venous access

          -  haemato-oncological malignancies

          -  patients who are unwilling to adhere to visit examination schedules . poor general
             condition (serious diseases - infections,cardiovascular or cerebral insufficience,
             severe IHD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Blaha, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University, Medical Faculty and Faculty Hospital, 50005 Hradec Kralove, CZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty Hospital</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Augood C, Fletcher A, Bentham G, Chakravarthy U, de Jong PT, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Young I. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol. 2004 Apr;11(2):117-29.</citation>
    <PMID>15255027</PMID>
  </reference>
  <reference>
    <citation>Bláha M, Cermanová M, Bláha V, Blazek M, Malý J, Siroký O, Solichová D, Filip S, Rehácek V. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial. 2007 Feb;11(1):9-15.</citation>
    <PMID>17309569</PMID>
  </reference>
  <reference>
    <citation>Blaha M, Zadak Z, Blaha V, Andrys C, Havel E, Vyroubal P, Blazek M, Filip S, Lanska M, Maly J. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atheroscler Suppl. 2009 Dec 29;10(5):17-20. doi: 10.1016/S1567-5688(09)71804-5.</citation>
    <PMID>20129368</PMID>
  </reference>
  <reference>
    <citation>Borberg H. 26 years of LDL--apheresis: a review of experience. Transfus Apher Sci. 2009 Aug;41(1):49-59. doi: 10.1016/j.transci.2009.05.013. Epub 2009 Jun 25.</citation>
    <PMID>19559652</PMID>
  </reference>
  <reference>
    <citation>Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007 Feb;114(2):253-62.</citation>
    <PMID>17270675</PMID>
  </reference>
  <reference>
    <citation>Friedman E. The pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2008 Sep;146(3):348-9. doi: 10.1016/j.ajo.2008.05.017.</citation>
    <PMID>18724980</PMID>
  </reference>
  <reference>
    <citation>Klingel R, Fassbender C, Fassbender T, Göhlen B. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfus Apher Sci. 2003 Aug;29(1):71-84. Review.</citation>
    <PMID>12877897</PMID>
  </reference>
  <reference>
    <citation>Klingel R, Fassbender C, Heibges A, Koch F, Nasemann J, Engelmann K, Carl T, Meinke M, Erdtracht B. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther Apher Dial. 2010 Jun;14(3):276-86. doi: 10.1111/j.1744-9987.2010.00807.x.</citation>
    <PMID>20609179</PMID>
  </reference>
  <reference>
    <citation>Koss MJ, Kurz P, Tsobanelis T, Lehmacher W, Fassbender C, Klingel R, Koch FH. Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART. Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1297-306. doi: 10.1007/s00417-009-1113-7. Epub 2009 Jul 23.</citation>
    <PMID>19629514</PMID>
  </reference>
  <reference>
    <citation>Rencová E., Bláha M., Rozsíval ry form age related macular degeneration with rheohemotherapy. (In Czech.) In Trendy soudobé oftalmologie 7. Praha: Galén, 2011, s. 16-31. ISBN 978- 80-7262- 691-5.</citation>
  </reference>
  <reference>
    <citation>Rencová E, Bláha M, Studnička J, Blažek M, Bláha V, Dusová J, Malý J, Kyprianou G, Vašátko T, Langrová H. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmol. 2011 Aug;89(5):463-71. doi: 10.1111/j.1755-3768.2009.01710.x. Epub 2010 Jan 22.</citation>
    <PMID>20102350</PMID>
  </reference>
  <reference>
    <citation>Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):18-26. doi: 10.1111/j.1442-9071.2011.02581.x. Review.</citation>
    <PMID>22304025</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <last_update_submitted>May 30, 2016</last_update_submitted>
  <last_update_submitted_qc>May 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Hradec Kralove</investigator_affiliation>
    <investigator_full_name>Karel Antos</investigator_full_name>
    <investigator_title>Deputy director</investigator_title>
  </responsible_party>
  <keyword>age-related macular degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>rheohemapheresis</keyword>
  <keyword>plasma filtration</keyword>
  <keyword>electroretinography</keyword>
  <keyword>ERG</keyword>
  <keyword>multifocal ERG</keyword>
  <keyword>double plasma filtration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

